<DOC>
	<DOCNO>NCT01905930</DOCNO>
	<brief_summary>On October 26 , 2012 , FDA grant Premarket Approval ( PMA ) PCM Cervical Disc . PCM Cervical Disc indicate use skeletally mature patient reconstruction degenerate cervical disc one level C3-C4 C6-C7 follow single-level discectomy intractable radiculopathy ( arm pain and/or neurological deficit ) , without neck pain , myelopathy due single-level abnormality localize disc space , manifest least one follow condition confirm radiographic imaging ( CT , MRI , X-rays ) : herniated nucleus pulposus , spondylosis ( define presence osteophyte ) , and/or visible loss disc height compare adjacent level . The purpose post-approval study evaluate long-term ( 7 year ) safety effectiveness PCM Cervical Disc .</brief_summary>
	<brief_title>Post-Approval Clinical Trial PCMÂ® Cervical Disc</brief_title>
	<detailed_description>A prospective , multi-center , post approval study concurrent control group consist patient enrol fail PCM Cervical Disc IDE clinical study give consent participate . All PCM IDE investigational site active patient choose participate study . All patient actively participate pivotal IDE study ask participate study . The study consist follow-up period . The follow-up period last seven year patient 's surgery date .</detailed_description>
	<mesh_term>Radiculopathy</mesh_term>
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<criteria>Patients enrol PCM Cervical Disc IDE clinical study Patients willing able give inform consent Patients consider failure PCM Cervical Disc IDE clinical study Patients withdraw PCM Cervical Disc IDE clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>